Abstract
The authors conducted a double-blind, placebo-controlled, crossover study to investigate the efficacy of oral zolmitriptan in the treatment of migraine in children and adolescents. Patients (n = 32) received placebo, zolmitriptan 2.5 mg, and ibuprofen 200 to 400 mg to treat three consecutive migraine attacks. Pain relief rates after 2 hours were 28% for placebo, 62% for zolmitriptan, and 69% for ibuprofen (p < 0.05). Both drugs are well tolerated with only mild side effects.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Adolescent
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Child
-
Double-Blind Method
-
Female
-
Humans
-
Ibuprofen / adverse effects
-
Ibuprofen / therapeutic use*
-
Migraine Disorders / drug therapy*
-
Oxazolidinones / adverse effects
-
Oxazolidinones / therapeutic use*
-
Serotonin Receptor Agonists / administration & dosage
-
Serotonin Receptor Agonists / therapeutic use
-
Tryptamines / adverse effects
-
Tryptamines / therapeutic use*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Oxazolidinones
-
Serotonin Receptor Agonists
-
Tryptamines
-
zolmitriptan
-
Ibuprofen